News

June 7, 2010

Aposense gains high valuation in successful IPO
The drug developer raised NIS 94 million at a company value of over NIS 900 million.
Yael Gruntman

Drug development company Aposense Ltd. yesterday completed its IPO on the Tel Aviv Stock Exchange (TASE) with a resounding success. The company raised a gross NIS 94 million at a company value of over NIS 900 million, after money.

Aposense develops molecular imaging techniques and drugs based on apoptosis (programmed cell death) to create personalized patient care in areas, such as oncology, cardiology and neurology. Eli Hurvitz is the company's chairman.

More News